GLPwatch

Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation.

Horm Metab Res · 2010

Last updated 2026-05-28

In lab tests, the drug exendin-4 (a GLP-1 analogue) protected pancreatic beta cells from damage caused by the immunosuppressant rapamycin. When cells were exposed to rapamycin for 12 hours, about half died, but adding exendin-4 at the same dose prevented this cell death. Exendin-4 worked by blocking the activation of proteins called JNK and p38, which rapamycin normally triggers.

AI summary of the abstract below.

JournalHorm Metab Res, 2010
Citations21
Relative citation ratio0.57
NIH percentile33
Molecules
Conditions studied Type 2 Diabetes

Abstract

It has been reported that the immunosuppressant rapamycin decreases the viability of pancreatic beta cells. In contrast, exendin-4, an analogue of glucagon-like peptide-1, has been found to inhibit beta cell death and to increase beta cell mass. We investigated the effects of exendin-4 on the cytotoxic effect of rapamycin in beta cells. Incubation with 10 nM rapamycin induced cell death in 12 h in murine beta cell line MIN6 cells and Wistar rat islets, but not when coincubated with 10 nM exendin-4. Rapamycin was found to increase phosphorylation of c-Jun amino-terminal kinase (JNK) and p38 in 30 minutes in MIN6 cells and Wistar rat islets while exendin-4 decreased their phosphorylation. Akt and extracellular signal-regulated kinase (ERK) were not involved in the cytoprotective effect of exendin-4. These results indicate that exendin-4 may exert its protective effect against rapamycin-induced cell death in pancreatic beta cells by inhibiting JNK and p38 signaling.

Verbatim abstract via PubMed 20213584 ↗